Transcode Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Transcode Therapeutics, Inc. (Nasdaq: RNAZ) on March 2, 2026. The filing details a strategic partnership and capital transaction involving the acquisition of a pre-clinical oncology asset and the issuance of new equity securities.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial activity reported is the issuance of equity as consideration for a licensing agreement:
- Asset Acquisition: Entered into an Exclusive Licensing Agreement with Unleash ImmunoOncolytics, Inc. for a pre-clinical candidate program involving genetically-engineered adenoviruses for cancer treatment.
- Consideration to Unleash: Issuance of 1,136,364 shares of Series C Non-Voting Convertible Preferred Stock.
- Consideration to Advisor: Issuance of 77,841 shares of Series C Preferred Stock to Tungsten Advisors as compensation for financial advisory services.
- Total Series C Issuance: 1,214,205 shares.
Material Changes and Capital Structure
The Company filed a Certificate of Designation for the Series C Preferred Stock with the Delaware Secretary of State. Key terms include:
- Dividends and Voting: The Series C stock carries no dividend rights and no general voting rights.
- Protective Provisions: Holders possess veto rights over actions that would adversely alter their preferences or rights, or amend the Charter/Bylaws in a manner detrimental to the Series C.
- Liquidation Preference: Ranks on parity with Common Stock, Series A, and Series B Preferred Stock.
- Conversion: Convertible into Common Stock on a 1:1 basis following stockholder approval (Unleash Stockholder Approval) and a three-business-day waiting period.
- Beneficial Ownership Limitation: Conversion is restricted if it would cause a holder to beneficially own more than 4.99% of the outstanding Common Stock, unless waived.
Guidance, Outlook, and Risks
Management has announced the transaction via press release (March 3, 2026) and expects to file a proxy statement to seek stockholder approval for the conversion of the Series C Preferred Stock into Common Stock, as required by Nasdaq listing rules. The filing notes that the securities were issued in reliance on Section 4(a)(2) of the Securities Act and have not been registered. The Company has agreed to file a Form S-3 registration statement for these shares.
Investor Verification Checklist
- Verify the terms of the upcoming proxy statement regarding the "Unleash Issuance Proposal" and the required stockholder vote.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific limitations on conversion and protective provisions.
- Confirm the status of the Form S-3 registration statement for the 1,214,205 shares of Series C Preferred Stock.
- Assess the potential dilution impact of the 1:1 conversion of Series C shares into Common Stock once approved.
- Examine the details of the pre-clinical candidate program acquired from Unleash to evaluate its strategic fit and development timeline.